Thalis Asimakopoulos

Dr. Thalis Asimakopoulos

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2025 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
TAThalis Asimakopoulos
Thalis Asimakopoulos
ATAthanasia Tsaroucha
Athanasia Tsaroucha
MKMaria Kouri
Maria Kouri
APAlberto Pasqualucci
Alberto Pasqualucci
GVGiustino Varrassi
Giustino Varrassi
Martina RekatsinaMartina Rekatsina
Martina Rekatsina
Acute pain, a critical aspect of patient care, presents a challenge due to its subjective nature and complex biological underpinnings. Biomarkers for acute pain promise a paradigm shift in how pain is perceived, diagnosed, and managed. The study of genetic, inflammatory, and neurotransmission markers associated with pain experience may hold the key for the development of personalized and effective pain management strategies. This narrative review explores the neurobiological pathways of acute pain, encompassing inflammatory responses and neurotransmission mechanisms. It synthesizes current research on the identification and clinical application of biomarkers, emphasizing their potential to enhance diagnostic precision, treatment effectiveness, and risk prediction. We underscore the promising role of acute pain biomarkers in identifying patients at risk for developing acute and potentially chronic pain, predicting patients’ response to pharmacological interventions, and aiding in the development of novel therapeutic and pain preventive strategies. The evolving landscape of biomarker research not only deepens our understanding of pain mechanisms but also lays the foundation for more tailored and patient-specific healthcare interventions.

18 March 2024 in Advancements in Health Research
Verified
Journal Article
Open access
PDF file
TAThalis Asimakopoulos
Thalis Asimakopoulos
MKMarianna Kourousi
Marianna Kourousi
GVGiustino Varrassi
Giustino Varrassi
Martina RekatsinaMartina Rekatsina
Martina Rekatsina
Piezo channels, a class of mechanosensitive ion channels, have emerged as key players in sensory transduction. Piezo1 and Piezo2 have been implicated in various physiological processes, including touch sensation and nociception. Their association with migraine and their role in pain involving trigeminal nerve have gained significant research attention. Following PRISMA guidelines, we performed a systematic review of the literature, on the role of Piezo1 and Piezo2 channels in migraine and trigeminal pain. From PubMed, Cochrane Library, and Scopus, we deemed 20 studies published between 2014 and 2023 appropriate to be included in this review. Piezo1 emerges as a key player in migraine pathogenesis, contributing to meningeal nociception and pain generation. In trigeminal pain syndromes, Piezo channels, particularly Piezo2, have a role in various pain conditions, from corneal nociception to dental and orofacial pain. Mechanistic insights provide potential therapeutic targets for migraine and other pain conditions involving trigeminal nerve. This systematic review accentuates the emerging significance of Piezo channels in migraine and trigeminal-associated pain, underscoring cross-associations that interconnect Piezo channels, migraine, and trigeminal neurons, as well as suggesting promising avenues for targeted therapeutic interventions and future research directions.

20 August 2023 in Cureus
Verified
Journal Article
Open access
PDF file
TAThalis Asimakopoulos
Thalis Asimakopoulos
AGAthanasia A Gika
Athanasia A Gika
PKPanayotis S. Kekelos
Panayotis S. Kekelos
IKIrene C. Kouroukli
Irene C. Kouroukli
The varicella-zoster virus can reactivate in patients with impaired cell-mediated immunity, resulting in herpes zoster (HZ) and sometimes in herpetic neuralgia (HN). Stellate ganglion blockade (SGB) has been studied for the treatment of HN and postherpetic neuralgia (PHN), but its effectiveness in preventing PHN in patients with acute HZ is not well-established. Here, we present a case of a 75-year-old woman who underwent SGB for HN of the right upper limb. The patient had been treated with antivirals and various analgesics, but adverse effects due to analgesics led to discontinuation of them. After the first application of SGB, the patient experienced significant pain reduction, and after a second application, complete remission of pain was achieved. Nine months later, the patient remained symptom-free and without PHN. The therapeutic potential of SGB in the treatment of HN and its role in preventing PHN requires further investigation.

26 February 2024 in Cureus
Verified
Journal Article
Open access
AGAliki Tympa Grigoriadou
Aliki Tympa Grigoriadou
TAThalis Asimakopoulos
Thalis Asimakopoulos
COChristina Orfanou
Christina Orfanou
AMAikaterini Melemeni
Aikaterini Melemeni
ATAthanasia Tsaroucha
Athanasia Tsaroucha
Neuromyelitis optica (NMO), also known as Devic disease, poses unique challenges in obstetrical anesthesia, with limited research available. This case report presents the anesthetic management of a 43-year-old gravida 2 para 1 (G2P1) woman with NMO undergoing labor induction at 39 weeks of gestation. Having received uneventful epidural labor analgesia in her first pregnancy, she faced the delicate decision of neuraxial anesthesia in light of her NMO diagnosis, which was made following her initial pregnancy. Collaborative discussions resulted in the choice of labor epidural analgesia, and an indwelling epidural catheter was placed successfully. An unplanned cesarean section with effective epidural supplementation followed. The case highlights the intricacies of balancing pain relief and neurological risks in NMO patients. Existing literature reflects varying perspectives on neuraxial anesthesia in NMO, with reports both supporting and cautioning against its use. The case aligns with the current view that epidural labor analgesia appears safe in NMO, but conclusive recommendations await larger studies. The decision for neuraxial anesthesia in NMO should be individualized, guided by comprehensive pre-anesthetic counseling and ongoing research developments.

17 June 2026 in Pain and Therapy
Verified
Journal Article
Open access
TAThalis Asimakopoulos
Thalis Asimakopoulos
ATAthanasia Tsaroucha
Athanasia Tsaroucha
MRMartina Rekatsina
Martina Rekatsina
Transcutaneous pulsed radiofrequency (TcPRF) is a non-invasive neuromodulation technique increasingly investigated for the management of chronic pain. However, its clinical efficacy and safety across different chronic pain conditions remains uncertain. A systematic search of PubMed, Scopus, and Google Scholar was performed from database inception to March 2026. Randomized controlled trials (RCTs) evaluating TcPRF in chronic pain conditions were included. Pain intensity, functional outcomes, and safety data were extracted. Risk of bias was assessed using the Cochrane RoB 2 tool. Eight RCTs were included, encompassing both musculoskeletal and neuropathic pain conditions. TcPRF was associated with reductions in pain intensity in most studies, with more consistent effects observed in sham-controlled trials and at later follow-up time points. Functional outcomes generally improved in parallel with pain, although results varied depending on the outcome measures used. TcPRF was well tolerated, with no serious adverse events reported. However, substantial heterogeneity was noted in patient populations, comparator interventions, treatment protocols, and outcome measures. TcPRF appears to be a promising non-invasive treatment option for selected chronic pain conditions, particularly when a minimally invasive approach is preferred. Nevertheless, current evidence remains limited by heterogeneity and methodological variability. Further large-scale, well-designed RCTs with standardized treatment protocols and longer follow-up are required to clarify its clinical role.

11 August 2026 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
TAThalis Asimakopoulos
Thalis Asimakopoulos
IPIliana Psychari
Iliana Psychari
MRMartina Rekatsina
Martina Rekatsina
ZKZinovia Kefalopoulou
Zinovia Kefalopoulou
Pain is a highly prevalent and disabling non-motor symptom of Parkinson’s disease (PD), yet it remains underrecognized and frequently undertreated in